Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31results about How to "Suitable as therapeutic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Implantation device for an aorta in an aortic arch
InactiveUS20030097170A1Simple and rapid simultaneous treatmentSpend less timeStentsBlood vesselsAortic arch aneurysmImplanted device
A stent made of a self-expandable or balloon-expandable metal mesh fabric that can be widened to a diameter larger than that of the descending aorta. The stent has a flexible lining of vessel-replacing material, wherein the lining covers it at least partly in longitudinal direction and forms a tubular segment which projects beyond the end of the stent at least at one end and which functions as the vascular prosthesis. Such implantable arrangements (1) make it possible to achieve short surgical times, especially during the treatment of aortic arch aneurysms involving the cephalic arteries.
Owner:CURATIVE
Method and material for in situ corneal structural augmentation
InactiveUS20080139671A1Augmenting shape and thicknessSuitable as therapeuticBiocideLaser surgeryOptical propertyMedicine
A method and material for augmenting the shape and thickness of the cornea in situ includes applying a clear liquid collagen mixed with a customized crosslinker onto the augmentation surface or in a cavity (with or without a mold) and exposing the mixture to UVA radiation in vivo. Application of UVA at varying dosages demonstrate progressive optically clear gelation and biomechanical adherence properties, and in vitro optical properties (RI), mechanical suture strength and rheometric parameters are comparable to native corneal stromal tissue. Photochemical corneal collagen augmentation according to the invention makes it suitable to reconstruct and strengthen diseased and damaged eyes, ulcerated corneas, as well as provide a substrate for refractive onlay / inlay procedures and lamellar transplantation.
Owner:PRIAVISION
Multi-roller massage device
InactiveUS20100274165A1Relieve painReduced areaRoller massageSuction-kneading massageMedicineMassage
A massage device is described which alleviates pain and may be used on different parts of the body. The massage device includes a first roller and a second roller, arranged in a substantially parallel configuration. Each roller has an inner body and a soft external layer, which may include foam. A left connector bar couples the left side ends of the first and the second rollers. A right connector bar couples the right side ends of both rollers. The right connector bar is arranged in a configuration substantially parallel to the left connector bar. A third roller may be added between the first and second rollers. A user may use the multi-roller massage device to apply pressure to sensitive areas, in order to alleviate pain and discomfort.
Owner:EVANS TIMOTHY C
CNS gene delivery using peripheral administration of AAV vectors
ActiveUS10208318B2Safe and convenientSuitable as therapeuticNervous disorderGene therapyGene deliveryTherapeutic protein
The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases.
Owner:GENETHON +1
Thermosensitive polymers for therapeutic use and methods of preparation
InactiveUS20060204555A1Risk minimizationReduce disruptionCell culture supports/coatingAbsorbent padsPolymer scienceWound dressing
A process for preparing a thermosensitive polymer from a microemulsion is provided. The microemulsion comprises a monomer capable of forming a thermosensitive polymer and a polymerizable surfactant. Additional comonomers may be included in the microemulsion to vary the properties of the polymers produced. The resulting thermosensitive polymers may be nanoporous. The polymers according to the invention are suitable for use in medical applications, including use as a wound dressing and for delivery of cells to a graft site.
Owner:AGENCY FOR SCI TECH & RES
Radiotherapy planning with improve accuracy
ActiveUS11285338B2Easy to controlSave resourcesDiagnostic recording/measuringSensorsGraphical user interfacePulse sequence
The present disclosure relates to a method for controlling a magnetic resonance imaging guided radiation therapy apparatus comprising a magnetic resonance imaging system. The method comprises: acquiring magnetic resonance data using the magnetic resonance imaging system and the pulse sequence from an imaging volume; segmenting the magnetic resonance data into a plurality of segments indicating respective tissues in the imaging volume; creating a bulk electron density map of the imaging volume from the plurality of segments; displaying the bulk electron density map and radiation dose distributions for the plurality of segments on a graphical user interface, wherein the radiation dose distributions are determined using the bulk electron density map; receiving a modification signal for modifying at least a first segment of the segments; recreating the bulk electron density map using the modified first segment, and recalculating the radiation dose distribution using the bulk electron density map; redisplaying the bulk electron density map and the radiation dose distributions on the graphical user interface.
Owner:KONINKLJIJKE PHILIPS NV
Novel Water-Soluble Fullerene, Process for Producing the Same and Active Oxygen Generator Containing the Fullerene
InactiveUS20080004345A1Increase power generation capacitySuitable as therapeuticBiocideMaterial nanotechnologyPhotodynamic therapyWater soluble
A water-soluble fullerene wherein the number of water-soluble polymers bonded has been regulated can be obtained by coupling water-soluble polymers with a fullerene having functional groups in its molecule via the functional groups. This water-soluble fullerene can be used in the photodynamic therapy or supersonic therapy of cancer through the use thereof as an active oxygen generator.
Owner:TABATA +2
Activator for mesenchymal stem cells, activated mesenchymal stem cells, and method for producing same
ActiveUS20170071984A1Proliferation potencySuitable as therapeuticSenses disorderNervous disorderDiseaseMesenchymal stem cell
[Problem] To activate an abnormal mesenchymal stem cell whose therapeutic effect is lost or reduced, or rather which has a disease-exacerbating effect so as to be in a state suitable for cell transplant therapy.[Solution] An activator for mesenchymal stem cells, mesenchymal stem cells activated by the activator, a method for producing the same, and a pharmaceutical containing the activated mesenchymal stem cells are provided.
Owner:SAPPORO MEDICAL UNIVERSITY
Controlled Release Hydrogels
InactiveUS20090104254A1Reduce molecular weightSuitable as therapeuticBiocidePharmaceutical non-active ingredientsControlled releaseMedicine
Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.
Owner:RUTGERS THE STATE UNIV
Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
InactiveUS20030215509A1Moderate weight and volumeEasy to swallowBiocideAnimal repellantsProlonged-release tabletExcipient
The present invention provides coated sustained release tablets of a hygroscopic compound for once-a-day therapy, said tablets having a moderate weight and volume and comprising-(a) a core comprising the hygroscopic compound and pharmaceutically acceptable excipients, (b) a first coating layer comprising a polymer selected from the group consisting of water-insoluble polymers, pH dependent polymers or a mixture thereof, and (c) a second coating layer comprising a water-insoluble polymer.
Owner:SUN PHARMA INDS
Compositions and methods for prevention and treatment of fungal diseases
InactiveUS20070243209A1Significant clinical importanceEffective adjuvantBiocideOrganic active ingredientsDiseaseFungal disease
The present invention relates to various pharmaceutical compositions that can be used as active or passive vaccines for the treatment or prevention of fungal disease. Methods for prevention and treatment of infectious and allergic fungal diseases in subjects using the pharmaceutical compositions of the present invention are also disclosed.
Owner:HEALTH RES INC
Stable solid units and methods of making the same
InactiveUS20160228371A1Maintain stabilityRetain activityPowder deliveryImmunoglobulins against cytokines/lymphokines/interferonsActive componentSugar
The invention provides stable solid compositions of a therapeutic agent, such as a protein, (e.g., an antibody, a peptide, or a DVD-Ig protein), and a stabilizer, such as a sugar, and methods of preparing and using the same. The invention further provides a generalized therapeutic agent delivery form wherein the active components are in a lyophilized, stable configuration, and, in some embodiments, prepared independently from the primary container.
Owner:ABBVIE INC
LeY SPECIFIC BIOTHERAPEUTIC
InactiveUS20120010388A1Weak affinityGood curative effectImmunoglobulins against cell receptors/antigens/surface-determinantsFermentationEpitopeBinding site
Embodiments are related to the field of immunology, and provide a highly avid LeY specific biotherapeutic including at least one further binding site having a different specificity to bind an epitope of a glycosylated cell surface molecule of a tumor cell, characterized by EC50 of less than 1 mM to confer immediate cytotoxicity to the tumor cell.
Owner:HIMMLER GOTTFRIED
Radiotherapy planning with improve accuracy
ActiveUS20180078787A1Easy to controlSave resourcesDiagnostic recording/measuringSensorsPhysicsGraphical user interface
The present disclosure relates to a method for controlling a magnetic resonance imaging guided radiation therapy apparatus comprising a magnetic resonance imaging system. The method comprises: acquiring magnetic resonance data using the magnetic resonance imaging system and the pulse sequence from an imaging volume; segmenting the magnetic resonance data into a plurality of segments indicating respective tissues in the imaging volume; creating a bulk electron density map of the imaging volume from the plurality of segments; displaying the bulk electron density map and radiation dose distributions for the plurality of segments on a graphical user interface, wherein the radiation dose distributions are determined using the bulk electron density map; receiving a modification signal for modifying at least a first segment of the segments; recreating the bulk electron density map using the modified first segment, and recalculating the radiation dose distribution using the bulk electron density map; redisplaying the bulk electron density map and the radiation dose distributions on the graphical user interface.
Owner:KONINKLJIJKE PHILIPS NV
Nucleic acid derivatives
InactiveUS7034131B2Easy to useEase of synthetic procedureBiocideSenses disorderNucleobase bindingBackbone chain
A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety selected from the group consisting of a naturally occurring nucleobase and a nucleobase binding group, wherein moieties of the one or more pair(s) are directly linked to one another via a linker chain; building blocks for synthesizing the compound; and rises of the compound, particularly in antisense therapy.
Owner:BIO RAD LAB INC
Thermosensitive polymers for therapeutic use and methods of preparation
InactiveUS8394366B2Easy to disassembleReduce the temperatureCell culture supports/coatingAbsorbent padsPolymer scienceWound dressing
A process for preparing a thermosensitive polymer from a microemulsion is provided. The microemulsion comprises a monomer capable of forming a thermosensitive polymer and a polymerizable surfactant. Additional comonomers may be included in the microemulsion to vary the properties of the polymers produced. The resulting thermosensitive polymers may be nanoporous. The polymers according to the invention are suitable for use in medical applications, including use as a wound dressing and for delivery of cells to a graft site.
Owner:AGENCY FOR SCI TECH & RES
Method and system for segmentation of the prostate in 3D magnetic resonance images
ActiveUS9025841B2Short processing timeSuitable as therapeuticImage enhancementImage analysisVoxelResonance
A method and system for fully automatic segmentation the prostate in multi-spectral 3D magnetic resonance (MR) image data having one or more scalar intensity values per voxel is disclosed. After intensity standardization of multi-spectral 3D MR image data, a prostate boundary is detected in the multi-spectral 3D MR image data using marginal space learning (MSL). The detected prostate boundary is refined using one or more trained boundary detectors. The detected prostate boundary can be split into patches corresponding to anatomical regions of the prostate and the detected prostate boundary can be refined using trained boundary detectors corresponding to the patches.
Owner:SIEMENS HEALTHCARE GMBH
Passive immunization for staphylococcus infections
ActiveUS20160311925A1Prevent adhesionInhibit growthAntibacterial agentsHydrolasesPassive ImmunizationsAntiendomysial antibodies
Disclosed herein are monoclonal antibodies or binding portion thereof that bind specifically to a Staphylococcus spp. autolysin N-acetylmuramoyl-L-alanine amidase catalytic domain and / or cell wall binding domain, as well as pharmaceutical compositions containing the same. Cell lines expressing the monoclonal antibodies, including hybridomas, are also disclosed. Methods of using the monoclonal antibodies for installation of orthopedic implants, grafts or medical devices, treating or preventing a Staphylococcus infection, and treating osteomyelitis are described, as are diagnostic methods for the detection of Staphylococcus in a sample.
Owner:UNIVERSITY OF ROCHESTER
Manufacturing and engineering of DNASE enzymes for therapy
ActiveUS10988746B2AmenableDelay EliminationHydrolasesPeptide/protein ingredientsExtracellular proteinsGranulocytic cells
The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and / or release. In accordance with the invention, the DNase variant has advantages for therapy and / or large-scale manufacturing.
Owner:NEUTROLIS INC
Production of insulin producing cells
InactiveUS9085757B2Easy to transplantSuitable as therapeuticBiocidePancreatic cellsProgenitorInsulin producing cell
The invention provides methods for differentiating stem cells along the pancreatic lineage as well as large scale culture methods. The present invention further provides pancreatic progenitor cells derived from stem cells to provide pancreatic cells to a subject.
Owner:RGT UNIV OF MINNESOTA
Production of insulin producing cells
ActiveUS20130243735A1Facilitate transplantationEasy to transplantBiocidePancreatic cellsPancreatic progenitor cellProgenitor
The invention provides methods for differentiating stem cells along the pancreatic lineage as well as large scale culture methods. The present invention further provides pancreatic progenitor cells derived from stem cells to provide pancreatic cells to a subject.
Owner:RGT UNIV OF MINNESOTA
Sterile gelling agents
InactiveUS20060286130A1Suitable as therapeuticBiocideEnergy modified materialsCompound (substance)Chemical property
This invention is directed to sterile gelling agents, which retain their physico-chemical properties so that they can be used in drug delivery systems. Also described are the processes for obtaining a sterile gelling agent(s).
Owner:WOCKHARDT LTD
Albumin-modified nanoparticles carrying a targeting ligand
InactiveUS20200282075A1Promote absorptionUptake by the cells of said organ or tissue can be increasedPowder deliveryPeptide/protein ingredientsPharmaceutical drugCombinatorial chemistry
The present invention relates to cargo substance-loaded, albumin-modified nanoparticles comprising a targeting ligand, to a method for producing such nanoparticles, to nanoparticles obtainable by said method, to a pharmaceutical composition containing a plurality of such nanoparticles and to the medical use of such nanoparticles.
Owner:ABBVIE DEUTSHLAND GMBH & CO KG
Myb-related transcription factor (MYPOP) as diagnostic marker and therapeutic target for tumor therapy
PendingUS20220003783A1Limits cells' permissivenessSuppression problemPeptide/protein ingredientsHydrolasesTumor therapyOncology
The invention relates to a method for the diagnosis or prognosis of a cancer comprising (i) determining a level of expression of Myb-related transcription factor (MYPOP) or a part thereof in a patient sample; (ii) comparing the level of MYPOP expression of the patient sample to levels of a normal sample; (iii) correlating the level of MYPOP expression in the patient sample relative to the levels in the normal sample with a positive or negative diagnosis or prognosis of cancer.
Owner:XPROT GMBH
Controlled release hydrogels
InactiveUS20150283077A1Reduce molecular weightSuitable as therapeuticBiocidePharmaceutical non-active ingredientsControl releaseMedicine
Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.
Owner:RUTGERS THE STATE UNIV
Phototherapy apparatus
InactiveUS20130268034A1Suitable therapeutic treatmentSufficient lightingLight therapyLight treatmentLight guide
Provided is a phototherapy apparatus capable of applying appropriate treatment. Specifically, the purpose of the present invention is to provide a phototherapy apparatus capable of easily supplying adequate treatment light even when a region to be treated is a bent region like finger joints of a patient having severe rheumatoid arthritis, thus making it possible to apply appropriate treatment. This phototherapy apparatus is configured to include: a light guide including a first surface on which an affected part is placed and a second surface on a back surface side of the first surface; a light source that outputs therapeutic light to enter an inside of the light guide body; and a light guide member that has softness and surface tackiness and is disposed on a part of the first surface.
Owner:PANASONIC HEALTHCARE HLDG CO LTD
Langerin+ Cell Targeting
PendingUS20210047620A1Efficient deliveryLow accessibilityMammal material medical ingredientsBlood/immune system cellsPharmaceutical drugLangerin
The present invention relates to the use of a vehicle for specific molecular targeting of Langerin+ cells, wherein the vehicle is capable of specifically binding to a Langerin+ cell, said vehicle comprising (a) at least one carrier and (b) at least one saccharide moiety-based conjugate for a targeted cargo delivery into a Langerin+ cell, as well as pharmaceutical compositions and uses comprising the inventive vehicle.
Owner:MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV
Myb-related transcription factor (MYPOP) as diagnostic marker and therapeutic target for tumor therapy
InactiveUS20200174016A1Increasing cell proliferationPromote growthPeptide/protein ingredientsHydrolasesTumor therapyMYB
Compositions and methods for detecting and inhibiting cancer include targeting the expression or biological activity of Myb-related transcription factor (MYPOP).
Owner:UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ +1
Passive immunization for Staphylococcus infections
ActiveUS10100127B2Promote phagocytosisInhibition of divisionAntibacterial agentsSpecial paperPassive ImmunizationsStaphylococcus cohnii
Owner:UNIVERSITY OF ROCHESTER
Beam irradiation apparatus and beam irradiation control method
InactiveUS8716679B2Small diameterEnsure correct executionStability-of-path spectrometersBeam/ray focussing/reflecting arrangementsBeam diameterLight beam
The beam irradiation apparatus is featured by including a transport pipe which is vacuum-evacuated to be used as a transport channel of a beam taken out from an accelerator, a quadrupole magnet which modulates the beam diameter of the beam so that the beam is incident on an irradiation target existing in the atmosphere while maintaining the focusing angle of the beam, and one or more longitudinally movable range shifters which are provided to be capable of changing the distance to the irradiation target of the beam, and which modulate the beam range by reducing the energy of the beam by allowing the beam to pass through the movable range shifter, and is featured in that the beam is irradiated onto the irradiation target by modulating the beam diameter and the beam range.
Owner:GUNMA UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com